CTIS2024-512479-11-00进行中（未招募）1 期
A Long-term Follow-up Study of Subjects With Malignancies Treated With CRISPR CAR Cellular Therapies - CRSP-ONC-LTF
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Able to understand and comply with protocol-required study procedures and voluntarily sign and date a written informed consent document., Must have received CRISPR CAR cellular therapy.
排除标准
- •There are no specific exclusion criteria.
研究者
相似试验
进行中（未招募）
1 期
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical TrialEUCTR2011-005287-21-SEBristol-Myers Squibb International Corporation1,000
进行中（未招募）
1 期
Three-year Follow-up Study of Subjects Who Participated in a Previous BMS-650032 or BMS-790052 Chronic Hepatitis C Clinical TrialEUCTR2011-005287-21-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO1,000
进行中（未招募）
1 期
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical TrialEUCTR2011-005287-21-IEBristol-Myers Squibb International Corporation1,000
未知
3 期
A Long-Term Follow-up Study of Subjects Who Participated in A Clinical Trial in Which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Was Administered for the Treatment of Chronic Hepatitis CChronic Hepatitis CJPRN-jRCT2080221866Bristol-Myers Squibb K.K.1,000
进行中（未招募）
1 期
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical TrialEUCTR2011-005287-21-GBBristol-Myers Squibb International Corporation1,000